2024-512101-60-00CompletedPhase 1
A study to learn how vamorolone affects the body, how safe it is and how it moves into, through and out of the body in healthy male participants
Source: EU CTIS (euclinicaltrials.eu) · Last updated 6 May 2024
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- First submitted
- 14 Mar 2024
- Start date
- 5 Jun 2024
- Lead sponsor
- Santhera Pharmaceuticals (Schweiz) AG
- EU CT number
- 2024-512101-60-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 30
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nuvisan GmbH | Neu-Ulm | Germany | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.